-+ 0.00%
-+ 0.00%
-+ 0.00%

IMMUNEERING CORP: IMM-1-104 IS CURRENTLY BEING EVALUATED IN A PHASE 2A CLINICAL TRIAL

Reuters·10/15/2024 12:00:01

Please log in to view news